Curated News
By: NewsRamp Editorial Staff
June 24, 2025
Medicus Pharma's Non-Invasive Skin Cancer Treatment Shows Promise
TLDR
- Medicus Pharma Ltd.'s innovative SkinJect microneedle patch offers a competitive edge in the $15 billion BCC treatment market with its non-invasive, cost-effective solution.
- SkinJect utilizes a patented dissolvable microneedle patch to deliver doxorubicin directly to tumor cells, demonstrating safety and efficacy in Phase I trials with Phase II underway.
- Medicus Pharma's SkinJect patch represents a significant advancement in skin cancer treatment, offering a less painful, non-surgical option that could improve millions of lives globally.
- Discover how Medicus Pharma's thumb-sized microneedle patch is revolutionizing skin cancer treatment, with promising Phase I results and a potential market impact of over $15 billion.
Impact - Why it Matters
This news is significant because it highlights a potential paradigm shift in the treatment of basal cell carcinoma, offering a less invasive, more cost-effective, and equally effective alternative to surgery. For the millions affected by BCC annually, this could mean quicker treatment times, reduced pain, and lower healthcare costs. Additionally, the expansion into veterinary medicine and strategic acquisitions underscore Medicus Pharma's commitment to addressing unmet medical needs across both human and animal health sectors, promising broader impacts on healthcare and investment opportunities.
Summary
Medicus Pharma Ltd., through its subsidiary SkinJect Inc., is pioneering a groundbreaking non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer in the U.S., affecting over 5 million people annually. Their innovative approach utilizes a patented dissolvable microneedle patch to deliver chemotherapy directly to the tumor site, offering a painless alternative to traditional surgery. Preliminary results from Phase I and ongoing Phase II trials show promising efficacy, with over 60% of participants achieving complete clinical clearance. This treatment not only promises to reduce the physical and financial burden on patients but also aims to significantly lower the recurrence rate of BCC. With the potential to disrupt a $15 billion market, Medicus is also exploring applications in veterinary medicine, targeting squamous cell carcinoma in horses, and expanding its portfolio through strategic acquisitions like Antev Ltd., which could unlock an additional $6 billion in market opportunities.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Medicus Pharma's Non-Invasive Skin Cancer Treatment Shows Promise
